

Jochen Schopohl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8900199/publications.pdf>

Version: 2024-02-01

83
papers

3,666
citations

126708

33
h-index

138251

58
g-index

83
all docs

83
docs citations

83
times ranked

3168
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved pasireotide response in USP8 mutant corticotroph tumours in vitro. <i>Endocrine-Related Cancer</i> , 2022, 29, 503-511.	1.6	11
2	Medical Therapy of Acromegaly in Germany 2019 – Data from the German Acromegaly Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 216-223.	0.6	7
3	Clinical Characteristics of Primary Hypophysitis – A Single-Centre Series of 60 Cases. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 234-240.	0.6	15
4	Adherence, Attitudes and Beliefs of Growth Hormone Deficient Patients – A Questionnaire-based Cohort Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 112-117.	0.6	16
5	Endocrinological diagnosis in acromegaly. , 2021, , 187-203.		0
6	Corticotroph tumor progression after bilateral adrenalectomy (Nelson’s syndrome): systematic review and expert consensus recommendations. <i>European Journal of Endocrinology</i> , 2021, 184, P1-P16.	1.9	32
7	Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2887-e2899.	1.8	5
8	Differences between immunotherapy-induced and primary hypophysitis – a multicenter retrospective study. <i>Pituitary</i> , 2021, , 1.	1.6	15
9	Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 224-233.	0.6	6
10	Time to Diagnosis in Cushing’s Syndrome: A Meta-Analysis Based on 5367 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e12-e22.	1.8	69
11	Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study. <i>Pituitary</i> , 2020, 23, 203-211.	1.6	17
12	Sleep in pituitary insufficient patients compared to patients with depression and healthy controls at baseline and after challenge with CRH. <i>Journal of Psychiatric Research</i> , 2020, 129, 124-128.	1.5	5
13	Drug treatment strategies for secondary diabetes in patients with acromegaly. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1883-1895.	0.9	5
14	Functional changes of the liver in the absence of growth hormone (GH) action – Proteomic and metabolomic insights from a GH receptor deficient pig model. <i>Molecular Metabolism</i> , 2020, 36, 100978.	3.0	23
15	Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study. <i>Pituitary</i> , 2019, 22, 542-551.	1.6	12
16	Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 365-374.	0.8	16
17	Determinants of the growth hormone nadir during oral glucose tolerance test in adults. <i>European Journal of Endocrinology</i> , 2019, 181, 55-67.	1.9	42
18	IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea. <i>Endocrine</i> , 2018, 60, 317-322.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 17-26.	5.5	116
20	De-masking oxytocin-deficiency in craniopharyngioma and assessing its link with affective function. <i>Psychoneuroendocrinology</i> , 2018, 88, 61-69.	1.3	37
21	A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. <i>New England Journal of Medicine</i> , 2018, 379, 428-439.	13.9	180
22	New and emerging drug therapies for Cushing's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1187-1200.	0.9	11
23	Macimorelin as a Diagnostic Test for Adult GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3083-3093.	1.8	71
24	Surviving ectopic Cushing's syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing's disease during long-term follow-up. <i>European Journal of Endocrinology</i> , 2018, 179, 109-116.	1.9	24
25	Assessment of lung function in a large cohort of patients with acromegaly. <i>European Journal of Endocrinology</i> , 2017, 177, 15-23.	1.9	8
26	Cystic Craniopharyngiomas: Microsurgical or Stereotactic Treatment?. <i>Neurosurgery</i> , 2017, 80, 733-743.	0.6	21
27	Anthropometric factors have significant influence on the outcome of the CRH-arginine test: establishment of normative data for an automated immunoassay specifically measuring 22 kDa human growth hormone. <i>European Journal of Endocrinology</i> , 2017, 176, 273-281.	1.9	8
28	Cushing's syndrome: a model for sarcopenic obesity. <i>Endocrine</i> , 2017, 57, 481-485.	1.1	26
29	Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry. <i>Pituitary</i> , 2017, 20, 635-642.	1.6	39
30	Body Image Perception in Acromegaly Is Not Associated with Objective Acromegalic Changes but Depends on Depressive Symptoms. <i>Neuroendocrinology</i> , 2017, 105, 115-122.	1.2	14
31	Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry. , 2017, 20, 635.		1
32	Update on the use of oral octreotide therapy for acromegaly. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 1-7.	1.2	1
33	Perspectives on investigational drugs for acromegaly. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 381-384.	1.9	5
34	ACTH after 15 min distinguishes between Cushing's disease and ectopic Cushing's syndrome: a proposal for a short and simple CRH test. <i>European Journal of Endocrinology</i> , 2015, 173, 197-204.	1.9	33
35	Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas. <i>European Journal of Endocrinology</i> , 2015, 172, 733-743.	1.9	36
36	Time to Recovery of Adrenal Function After Curative Surgery for Cushing's Syndrome Depends on Etiology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1300-1308.	1.8	65

#	ARTICLE	IF	CITATIONS
37	Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. <i>Pituitary</i> , 2015, 18, 604-612.	1.6	46
38	Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1699-1708.	1.8	144
39	Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey. <i>European Journal of Endocrinology</i> , 2015, 172, 351-356.	1.9	35
40	Treatment of Primary Hypophysitis in Germany. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3460-3469.	1.8	88
41	The Incidence of Cancer Among Acromegaly Patients: Results From the German Acromegaly Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3894-3902.	1.8	60
42	Life-threatening events in patients with pheochromocytoma. <i>European Journal of Endocrinology</i> , 2015, 173, 757-764.	1.9	84
43	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1262-E1269.	1.8	4
44	A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2015, 173, M23-M32.	1.9	74
45	Frequency of AIP Gene Mutations in Young Patients With Acromegaly: A Registry-Based Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2789-E2793.	1.8	41
46	Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. <i>European Journal of Endocrinology</i> , 2014, 171, 209-215.	1.9	83
47	Emerging drugs for acromegaly. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 79-97.	1.0	9
48	Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open-label, phase I study. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1308-1317.	1.0	28
49	Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. <i>Pituitary</i> , 2014, 17, 132-140.	1.6	43
50	Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. <i>Clinical Endocrinology</i> , 2014, 81, 408-417.	1.2	95
51	Use of Therapeutic Hypothermia After In-Hospital Cardiac Arrest. <i>Critical Care Medicine</i> , 2014, 42, e545-e546.	0.4	2
52	Health Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life. <i>Frontiers in Endocrinology</i> , 2014, 5, 229.	1.5	42
53	Outcome of Bilateral Adrenalectomy in Cushing's Syndrome: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3939-3948.	1.8	163
54	Discriminatory value of signs and symptoms in Cushing's syndrome revisited: what has changed in 30 years?. <i>Clinical Endocrinology</i> , 2013, 78, 153-154.	1.2	10

#	ARTICLE	IF	CITATIONS
55	Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. <i>European Journal of Endocrinology</i> , 2013, 168, 39-47.	1.9	99
56	Clinical experience with lanreotide for the treatment of acromegaly. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 139-149.	1.2	1
57	Automated 22-kD Growth Hormone-Specific Assay without Interference from Pegvisomant. <i>Clinical Chemistry</i> , 2012, 58, 1446-1456.	1.5	59
58	Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. <i>Clinical Endocrinology</i> , 2011, 75, 825-830.	1.2	28
59	A Novel Approach to the Detection of Acromegaly: Accuracy of Diagnosis by Automatic Face Classification. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2074-2080.	1.8	92
60	Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52-week open extension. <i>Pituitary</i> , 2010, 13, 18-28.	1.6	120
61	Comparison of glucose and lipid metabolism and bone mineralization in patients with growth hormone deficiency with and without long-term growth hormone replacement. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 350-358.	1.5	14
62	Chronic Growth Hormone Excess Is Associated with Increased Aldosterone: A Study in Patients with Acromegaly and in Growth Hormone Transgenic Mice. <i>Experimental Biology and Medicine</i> , 2009, 234, 1002-1009.	1.1	27
63	Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. <i>Clinical Endocrinology</i> , 2009, 71, 691-701.	1.2	77
64	Outcome in elderly patients with severe infection is influenced by sex hormones but not gender. <i>Critical Care Medicine</i> , 2005, 33, 2786-2793.	0.4	85
65	Selenium substitution has no direct effect on thyroid hormone metabolism in critically ill patients. <i>European Journal of Endocrinology</i> , 2004, 151, 47-54.	1.9	47
66	Transcatheter closure of a ruptured ventricular septum following inferior myocardial infarction and cardiogenic shock. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 60, 224-228.	0.7	8
67	Thyrotoxicosis Induced by Thyroid Involvement of Disseminated <i>Aspergillus fumigatus</i> Infection. <i>Journal of Clinical Microbiology</i> , 2000, 38, 886-887.	1.8	17
68	Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. <i>Critical Care Medicine</i> , 1999, 27, 1807-1813.	0.4	245
69	Suppression of vagus-mediated pancreatic polypeptide release by the μ -opioid receptor agonist loperamide in man. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 371-377.	1.1	10
70	Immunoreactive inhibin in human follicular fluid in an ovarian hyperstimulation programme for in vitro fertilization: correlations and different forms. <i>European Journal of Endocrinology</i> , 1993, 128, 433-438.	1.9	3
71	Nocturnal Asthma. <i>Chest</i> , 1991, 100, 1239-1245.	0.4	24
72	Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma. <i>Clinical Endocrinology</i> , 1991, 34, 463-467.	1.2	14

#	ARTICLE	IF	CITATIONS
73	Growth-hormone releasing hormone in a bronchial carcinoid. <i>Cancer</i> , 1991, 67, 2538-2542.	2.0	17
74	Presence of Growth Hormone-Releasing Hormone-Like Immunoreactivity in Human Tumors: Characterization of Immunological and Biological Properties*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 62-68.	1.8	26
75	Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly. <i>Journal of Neurosurgery</i> , 1989, 70, 561-567.	0.9	61
76	INTERACTION OF CLONIDINE AND GHRH ON GH SECRETION IN VIVO AND IN VITRO. <i>Clinical Endocrinology</i> , 1989, 30, 485-491.	1.2	39
77	Effects of repetitive administration of thyrotropin-releasing hormone at short intervals in acromegaly. <i>European Journal of Endocrinology</i> , 1989, 120, 383-389.	1.9	1
78	Arginine Stimulates Growth Hormone Secretion by Suppressing Endogenous Somatostatin Secretion*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 67, 1186-1189.	1.8	335
79	Corticotropin-releasing factor (CRF): Stimulation in normal controls and in patients with Cushing's syndrome. <i>Psychoneuroendocrinology</i> , 1986, 11, 49-60.	1.3	28
80	Intravenous Application of Ovine and Human Corticotropin Releasing Factor (CRF): ACTH, Cortisol and CRF Levels. <i>Neuroendocrinology</i> , 1986, 42, 1-5.	1.2	31
81	Growth Hormone (GH) and Prolactin Responses to Repetitive Administration of GH-Releasing Hormone in Acromegaly*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 63, 475-480.	1.8	20
82	Growth hormone releasing factor induces prolactin secretion in acromegalic patients but not in normal subjects. <i>European Journal of Endocrinology</i> , 1985, 109, 467-473.	1.9	31
83	Growth hormone releasing factor infusion does not sustain elevated GH-levels in normal subjects. <i>European Journal of Endocrinology</i> , 1984, 107, 462-470.	1.9	52